Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 19/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.79 |
| ▸ | TNF | P01375 | 1/20 | 0.79 |
| ▸ | IL1B | P01584 | 1/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.79 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178641 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2049711 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2049712 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| Hydrochloric Acid SCHEMBL28784243 | 0.99 | DDB1 (0.97) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18270888 | 0.94 | DDB1 (0.88) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19370917 | 0.89 | DDB1 (0.81) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19250991 | 0.89 | DDB1 (0.80) | DDB1CRBNIKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930065 | 0.88 | CRBN (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| Pomalidomide SCHEMBL369172 | 0.88 | CRBN (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| Pomalidomide SCHEMBL563317 | 0.88 | CRBN (1.00) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| CN-108350062-B | Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy | 达纳-法伯癌症研究所股份有限公司 | 2022-10-14 | — | — | CN | disclosed |